Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

被引：56
|
作者：
Alva, A. [1 ]
Csoszi, T. [2 ]
Ozguroglu, M. [3 ]
Matsubara, N. [4 ]
Geczi, L. [5 ]
Cheng, S. Y-S. [6 ]
Fradet, Y. [7 ]
Oudard, S. [8 ]
Vulsteke, C. [9 ]
Morales Barrera, R. [10 ]
Flechon, A. [11 ]
Gunduz, S. [12 ]
Loriot, Y. [13 ]
Rodriguez-Vida, A. [14 ]
Mamtani, R. [15 ]
Yu, E. Y. [16 ]
Nam, K. [17 ]
Imai, K. [18 ]
Moreno, B. H. [19 ]
Powles, T. B. [20 ]
机构：
[1] Univ Michigan, Hematol Oncol, Ann Arbor, MI 48109 USA
[2] Hetenyi G Korhaz Onkol Kozpont, Oncol, Szolnok, Hungary
[3] Istanbul Univ Cerrahpasa, Med Oncol, Cerrahpasa Sch Med, Istanbul, Turkey
[4] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan
[5] Natl Inst Oncol Hungary, Med Oncol, Budapest, Hungary
[6] Sunnybrook Odette Canc Ctr, Oncol, Toronto, ON, Canada
[7] Univ Laval, CHU Quebec, Surg Urol, Quebec City, PQ, Canada
[8] Hop European George Pompidou, Immunotherapie & Traitement Antiangiogen Pathol C, Paris, France
[9] Ctr Oncol Res CORE, Antwerp, Belgium
[10] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[11] Ctr Leon Berard, Dept Med Oncol, Rhones Alpes, France
[12] Mem Antalya Hosp, Dept Med Oncol, Antalya, Turkey
[13] Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[14] Hosp del Mar, Dept Med Oncol, Barcelona, Spain
[15] Univ Penn, Abramson Canc Ctr, Hematol Oncol, Philadelphia, PA 19104 USA
[16] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA
[17] Merck & Co Inc, Stat, Kenilworth, NJ USA
[18] Merck & Co Inc, Clin Res Oncol Dept, Kenilworth, NJ USA
[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[20] Queen Mary Univ London, Barts Canc Inst, Dept Med Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2252
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA23
引用
收藏
页码：S1155 / S1155
页数：1
相关论文
共 50 条
  • [41] Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis.
    Eto, Masatoshi
    Lee, Jae-Lyun
    Park, Se Hoon
    Tsuchiya, Norihiko
    Su, Po-Jung
    Chan, T. W.
    Desai, Chirag Jyotiker
    Di Pietro, Alessandra
    Wang, Jing
    Laliberte, Robert J.
    Gao, Seasea
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] Avelumab first-line (1L) maintenance therapy in advanced urothelial carcinoma: Final analysis from a real-world study in the UK.
    Jones, Robert Jones
    Shah, Yatri
    Birtle, Alison Jane
    Challapalli, Amarnath
    Chan, Joachim
    Enting, Deborah
    Hudson, Andrew
    Linch, Mark David
    Otter, Sophie
    Protheroe, Andrew
    Sharma, Anand
    Turner, Rufus
    Chengat Prakashbabu, Bhagyalakshmi
    Rice, Wendy
    Jedy-Agba, Elima Enaji
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [43] Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
    Nishii, Yoichi
    Furuhashi, Kazuki
    Ito, Kentaro
    Sakaguchi, Tadashi
    Suzuki, Yuta
    Fujiwara, Kentaro
    Yasuma, Taro
    Kobayashi, Tetsu
    D'Alessandro-Gabazza, Corina N.
    Gabazza, Esteban C.
    Taguchi, Osamu
    Hataji, Osamu
    PHARMACEUTICALS, 2022, 15 (07)
  • [44] Phase 3 KEYNOTE-042 Study: Pembrolizumab vs Platinum-Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD-L1 TPS ≥1%
    Lopes, G.
    Wu, Y.
    Kudaba, I.
    Kowalski, D.
    Cho, B.
    Turna, H.
    De Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K.
    Bondarenko, I.
    Kubota, K.
    Lubiniecki, G.
    Zhang, J.
    Kush, D.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S152
  • [45] Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).
    O'Donnell, Peter H.
    Grivas, Petros
    Balar, Arjun Vasant
    Bellmunt, Joaquim
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    De Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Lunceford, Jared K.
    Keefe, Stephen Michael
    Bajorin, Dean F.
    Castellano, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Van Cutsem, E.
    Valderrama, A.
    Bang, Y-J.
    Fuchs, C.
    Shitara, K.
    Janjigian, Y. Y.
    Qin, S.
    Larson, T.
    Shankaran, V.
    Stein, S.
    Norquist, J. M.
    Kher, U.
    Shah, S.
    Alsina, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 879 - 879
  • [47] Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
    Grivas, P.
    Plimack, E.
    Balar, A. V.
    Castellano, D.
    O'Donnell, P. H.
    Bellmunt, J.
    Powles, T.
    Hahn, N.
    de Wit, R.
    Bajorin, D.
    Ellison, M. C.
    Frenkl, T.
    Keefe, S. M.
    Vuky, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Maintenance avelumab plus best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
    Powles, Thomas
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Valderrama, B. P.
    Gurney, Howard
    Kalofonos, Haralabos
    Radulovic, Sinisa
    Demey, Wim
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Kopyltsov, Evgeny
    Sternberg, Cora N.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel Peter
    di Pietro, Alessandra
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
  • [49] Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC)
    Naqvi, Syed Arsalan Ahmed
    Faisal, Kunwer Sufyan
    Raina, Ammad
    Khakwani, Kaneez Zahra Rubab
    Bin Riaz, Zaryab
    Shah, Vishal S.
    Cobran, Ewan Kemar
    Singh, Parminder
    Hussain, Syed A.
    Bryce, Alan Haruo
    Bin Riaz, Irbaz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M. E.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345